Hepion Pharmaceuticals Inc (HEPA NASDAQ) stock market data APIs
$0.7778
-0.02(-2.5%)
as of March 21, 2025
Hepion Pharmaceuticals Inc Financial Data Overview
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Prev. Close
0.8016
Open
0.7778
High
0.8335
Low
0.726
52 wk Range
0.671-144.995
Market Cap
895 K
Shares Outstanding
1 080 K
EPS
-0.7242
Beta
1.628
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Hepion Pharmaceuticals Inc data using free add-ons & libraries
Get Hepion Pharmaceuticals Inc Fundamental Data
Hepion Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -25 319 996
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-18
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hepion Pharmaceuticals Inc News
New
Hepion Pharmaceuticals Announces Reverse Stock Split
Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biophar...
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeuti...
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
- Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test ...
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeuti...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
